- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04854928
Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.
A Double-blind, Placebo-controlled, Interventional Parallel Group Study to Evaluate the Antiviral Effect of a Single Nasal Application of LTX-109 3% Gel, in Comparison to Placebo Gel, in Subjects With COVID-19 Infection.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A total of 60 subjects will be randomised to achieve approximately 46 completed and evaluable subjects. Subjects will be randomised 1:1 to one single dose of either active treatment or placebo.
All potential study subjects will be contacted and invited to a screening video-call with the Investigator. Full verbal information will be given and the consent for participation in the study will be signed electronically.
Eligible subjects will be visited twice at home by a study nurse on Day 1. During the first visit, one standard deep nose swab (one nostril) and one from the anterior part of the nose (both nostrils) will be collected. Symptom score will be assessed by the subject before dosing. The investigational medicinal product (IMP) will then be applied topically to both nostrils by the study nurse.
The study nurse will come back to collect nasal swab samples 2 hours after administration of the IMP, using the same sampling procedure as for the baseline samples.
Subjects will use an electronic diary for daily registrations of adverse events, concomitant medications and symptom score until Day 7.
A follow-up phone contact will be performed 7 days after IMP administration.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Christian Lütken, MD
- Phone Number: +47 48 000 242
- Email: Christian.lutken@pharmaholdings.no
Study Contact Backup
- Name: Johnny Ryvoll, MBA, B.Sc..
- Phone Number: +47 90 13 02 43
- Email: ryvoll@pharmaholdings.no
Study Locations
-
-
-
Uppsala, Sweden, SE-752 37
- Recruiting
- ClinSmart Sweden AB
-
Principal Investigator:
- Mahir Vazda
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing and able to give electronically signed informed consent for participation in the study.
- Male or female subject ≥18 years of age at screening.
- Women of child-bearing potential have to agree to use an acceptable birth control method during participation in the investigation and a negative pregnancy test (beta human chorionic gonadotropin dipstick test in urine) at Day 1 will be required.
- A positive PCR test (polymerase chain reaction test) or antigen test for SARS-CoV-2. The positive result must be available no later than 4 days from initiation of symptoms, if any.
- Duration of symptoms not exceeding 6 days prior to baseline/IMP administration (Day 1).
- Access to a mobile phone or computer and ability to use the electronic diary application and to participate in web-based appointments.
Exclusion Criteria:
- History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
- Other upper respiratory tract infection with concomitant symptoms that can influence the results, such as sinusitis or tonsillitis.
- Known allergy or hypersensitivity to the components of the IMP.
- Current use of immunosuppressive therapy within the last 4 weeks prior to Day 1 and during the study.
- Current use of nasally administered drugs within the last 2 weeks prior to Day 1 and during the study.
- Vaccinated against COVID-19 or scheduled for vaccination within the study period.
- Previous COVID-19 infection.
- Any systemic anti-viral treatment within the last 4 weeks prior to Day 1 and during the study.
- Pregnant, nursing or actively trying to conceive a child.
- Inability to take medications nasally.
- In situ nasal jewellery or open nasal piercings.
- Planned treatment or treatment with another investigational drug within 30 days prior to Day 1. Subjects consented and screened but not dosed in previous Phase I studies are not excluded.
- Investigator considers the subject unlikely to comply with study procedures, restrictions and requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LTX-109 treatment
Single Dose by Nasal application of LTX-109 gel 3%, 250 microliters in each nostril.
|
A Single dose of LTX-109 gel will be applied topically to both nostrils by a qualified health professional.
A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
|
Placebo Comparator: Placebo
Single Dose by Nasal application of placebo gel, 250 microliters in each nostril.
|
A Single dose of placebo gel will be applied topically to both nostrils by a qualified health professional.
A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2 ) viral load in the deep nasal cavity as measured by the amount of live virus in the samples.
Time Frame: From baseline (pre-dose) to 2 hours (h) post-dose
|
Assessment of viral load at baseline (pre-dose) and 2h post-dose to evaluate the effect of a single dose of LTX-109 nasal gel as compared to placebo.
Reduction in SARS-CoV-2 viral load is measured by a standardised reverse transcription quantitative polymerase chain reaction (RT-qPCR) method and virus titration followed by cell viability assay to quantify the amount of live virus in the samples (Median Tissue Culture Infectious Dose [TCID50]).
Viral load will be expressed as TCID50/mL.
|
From baseline (pre-dose) to 2 hours (h) post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in SARS-CoV-2 viral load in the anterior nasal cavity as measured by the amount of live virus in the samples.
Time Frame: From baseline (pre-dose) to 2 hours (h) post-dose
|
Assessment of viral load at baseline (pre-dose) and 2h post-dose to evaluate the effect of a single dose of LTX-109 nasal gel as compared to placebo.
Reduction in SARS-CoV-2 viral load is measured by a standardised RT-qPCR method and virus titration followed by cell viability assay to quantify the amount of live virus in the samples, TCID50.
Viral load will be expressed as TCID50/mL.
|
From baseline (pre-dose) to 2 hours (h) post-dose
|
Assessment of safety and tolerability by frequency and seriousness of Adverse Events (AE)
Time Frame: From dosing until 7 days after dose.
|
The Investigator will assess the seriousness of all AE according to the common definition of Serious Adverse Events (SAE).
Frequency of AEs and SAEs will be summarised by treatment and overall.
|
From dosing until 7 days after dose.
|
Assessment of safety and tolerability by intensity of AE
Time Frame: From dosing until 7 days after dose.
|
The Investigator will assess the intensity of an AE on a 5 graded scale.
Grade refers to the severity of the AE, from Grade 1 (mild) through Grade 5 (death).
|
From dosing until 7 days after dose.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Symptom score for frequency of COVID-19 infection symptoms.
Time Frame: From pre-dose on Day 1 until Day 7.
|
Daily assessments of frequency of symptoms using a study-specific questionnaire with 10 questions/symptoms.
Symptoms included are fever, cough, trouble breathing, loss of smell or taste, nasal congestion or runny nose, sore throat and/or difficulty swallowing, headache, muscle and/or joint pain, stomach-ache and/or nausea and diarrhoea.
The frequency of each symptom will be graded by the Subject using a 5 graded scale from Grade 1 (None of the time) through Grade 5 (All of the time).
For each symptom, the absolute and percent change from baseline to Day 7 will be calculated.
|
From pre-dose on Day 1 until Day 7.
|
Change in Symptom score for intensity of COVID-19 infection symptoms.
Time Frame: From pre-dose on Day 1 until Day 7.
|
Daily assessments of intensity of symptoms using a study-specific questionnaire with 10 questions/symptoms.
Symptoms included are fever, cough, trouble breathing, loss of smell or taste, nasal congestion or runny nose, sore throat and/or difficulty swallowing, headache, muscle and/or joint pain, stomach-ache and/or nausea and diarrhoea.
The intensity of each symptom will be graded by the Subject using a 5 graded scale from Grade 1 (Not at all intense) through Grade 5 (Terribly intense).
For each symptom, the absolute and percent change from baseline to Day 7 will be calculated.
|
From pre-dose on Day 1 until Day 7.
|
Reduction in SARS-CoV-2 viral load in the deep nasal cavity as measured by qPCR.
Time Frame: From baseline (pre-dose) to 2 hours (h) post-dose
|
Assessment of viral load at baseline (pre-dose) and 2h post-dose to evaluate the effect of a single dose of LTX-109 nasal gel as compared to placebo.
Reduction in SARS-CoV-2 viral load is measured by a qPCR.
Viral load will be expressed as log10 RNA copies per 1000 cells.
|
From baseline (pre-dose) to 2 hours (h) post-dose
|
Reduction in SARS-CoV-2 viral load in the anterior nasal cavity as measured by qPCR.
Time Frame: From baseline (pre-dose) to 2 hours (h) post-dose
|
Assessment of viral load at baseline (pre-dose) and 2h post-dose to evaluate the effect of a single dose of LTX-109 nasal gel as compared to placebo.
Reduction in SARS-CoV-2 viral load is measured by a qPCR.
Viral load will be expressed as log10 RNA copies per 1000 cells.
|
From baseline (pre-dose) to 2 hours (h) post-dose
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Christian Lütken, MD, Pharma Holdings AS
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C21-109-09
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on LTX-109 gel, 3%
-
Pharma Holdings ASUniversity Hospital of North NorwayCompleted
-
Pharma Holdings ASCTC Clinical Trial Consultants ABCompletedA Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of StaphylococcusNasal Decolonization of Staphylococcus AureusSweden
-
Pharma Holdings ASCTC Clinical Trial Consultants ABCompletedNasal Decolonization of Staphylococcus AureusSweden
-
Lytix Biopharma ASCompletedNon-bullous ImpetigoDominican Republic
-
Lytix Biopharma ASCompletedAtopic Dermatitis | Gram-positive, Skin Infections | Mild Eczema/DermatosesHungary
-
Lytix Biopharma ASCompleted
-
Starpharma Pty LtdCompletedRecurrent Bacterial Vaginosis (BV)
-
Starpharma Pty LtdNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompletedHealthyUnited States, Puerto Rico
-
Starpharma Pty LtdNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV Infections | HSV-2 Genital HerpesAustralia
-
Lakewood-Amedex IncPrimeVigilance; Professional Education and Research InstituteTerminated